Oncotec Pharma Produktion — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Oncotec Pharma Produktion is a privately held, revenue-generating CDMO focused exclusively on the oncology sector, providing end-to-end contract development and manufacturing services for sterile injectables. Founded in 1997 (with the provided data of 2006 likely being an incorporation or restructuring date), the company operates from a significant cleanroom facility in Dessau-Roßlau, Germany, employing over 250 people. Its technological edge lies in advanced aseptic filling under isolator protection, lyophilization capabilities, and a comprehensive analytical suite, positioning it as a specialized partner for pharmaceutical companies developing complex oncology drugs, including ADCs and cytostatics.

Oncology

Technology Platform

Specialized CDMO platform for aseptic manufacturing of sterile injectable oncology drugs. Core technologies include isolator-protected filling lines, lyophilization (freeze-drying) capabilities, and a comprehensive analytical suite. The platform supports development, clinical, and commercial manufacturing, with a focus on cytostatics and planned capabilities for Antibody-Drug Conjugates (ADCs).

Opportunities

Growing global demand for outsourced manufacturing of complex injectable oncology drugs, particularly Antibody-Drug Conjugates (ADCs), presents a significant expansion opportunity.

The company's EU-based, 'Made in Germany' quality reputation is a key asset for clients seeking reliable supply under EMA regulations.

Planned capacity expansions in lyophilization and ready-to-fill syringes can capture additional market segments.

Risk Factors

Revenue is contingent on the success and regulatory approval of clients' drug pipelines, creating dependency risk.

Operating in a highly regulated environment for sterile injectables exposes the company to significant compliance and quality risks, where any major deviation could impact operations.

Intense competition from larger global CDMOs and other specialized manufacturers pressures pricing and requires continuous technological investment.

Competitive Landscape

Oncotec competes in the niche but competitive CDMO market for sterile injectable oncology drugs. Key competitors include large, global CDMOs like Lonza, Catalent, and Recipharm, as well as other European specialists with expertise in potent compound manufacturing. Its differentiation lies in its focused oncology expertise, integrated 'single-source' services, and advanced isolator technology within a strategically located German facility.

More companies in Oncology (General) →More companies in Germany →